Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Nutr ; 48(1): 6-11, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19083041

RESUMO

BACKGROUND: The formation and accumulation of advanced glycation end products (AGEs) increase in some lifestyle-related diseases as well as in aging; however, little is known about the relationship between food-derived AGEs and the pathology of such diseases. AIM OF THE STUDY AND METHODS: To explore whether food items containing high levels of AGEs are involved in the development of lifestyle-related diseases, rats were orally administered a commercial high-AGE beverage [Lactobacillus beverage-A (LB-A)]. With a particular focus on angiogenesis-associated diseases, the gene expressions of vascular endothelial growth factor (VEGF) and the receptor for AGEs (RAGE) were examined in the liver and kidneys using real-time reverse transcription-polymerase chain reaction. Moreover, AGE deposition was immunohistochemically investigated in these tissues. RESULTS AND CONCLUSIONS: Hepatic VEGF expression was significantly increased in rats administered LB-A (P < 0.01 vs. control). Furthermore, immunohistochemical analysis detected glucose-derived AGE-positive cells in the liver from the LB-A group. These results suggest that AGE-rich beverages increase hepatic VEGF expression and AGE accumulation, bringing about early events associated with lifestyle-related diseases.


Assuntos
Bebidas/análise , Produtos Finais de Glicação Avançada/administração & dosagem , Rim/química , Fígado/química , Receptores Imunológicos/genética , Fator A de Crescimento do Endotélio Vascular/genética , Animais , Expressão Gênica/efeitos dos fármacos , Produtos Finais de Glicação Avançada/análise , Imuno-Histoquímica , Masculino , RNA Mensageiro/análise , Ratos , Ratos Sprague-Dawley , Receptor para Produtos Finais de Glicação Avançada , Reação em Cadeia da Polimerase Via Transcriptase Reversa
2.
Diabetes ; 55(8): 2245-55, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16873687

RESUMO

Angiogenic response is impaired in diabetes. Here, we examined the involvement of receptor for advanced glycation end products (RAGE) in diabetes-related impairment of angiogenesis in vivo. Angiogenesis was determined in reconstituted basement membrane protein (matrigel) plugs containing vascular endothelial growth factor (VEGF) implanted into nondiabetic or insulin-deficient diabetic wild-type or RAGE(-/-) mice. The total, endothelial, and smooth muscle (or pericytes) cells in the matrigel were significantly decreased in diabetes, with the regulation dependent on RAGE. In the matrigel, proangiogenic VEGF expression was decreased, while antiangiogenic thrombospondin-1 was upregulated in diabetic mice, regardless of the presence of RAGE. In wild-type mice, proliferating cell nuclear antigen (PCNA)-positive cells in the matrigel were significantly less in diabetic than in nondiabetic mice, while the numbers of transferase-mediated dUTP nick-end labeling (TUNEL)-positive cells were significantly higher. This alteration in PCNA- and TUNEL-positive cells in diabetes was not observed in RAGE(-/-) mice. Similarly, the percentage of nuclear factor kappaB-activated cells is enhanced in diabetes, with the regulation dependent on the presence of RAGE. Importantly, adenovirus-mediated overexpression of endogenous secretory RAGE, a decoy receptor for RAGE, restores diabetes-associated impairment of angiogenic response in vivo. Thus, RAGE appears to be involved in impairment of angiogenesis in diabetes, and blockade of RAGE might be a potential therapeutic target.


Assuntos
Diabetes Mellitus Experimental/fisiopatologia , Neovascularização Fisiológica/fisiologia , Receptores Imunológicos/fisiologia , Adenoviridae/genética , Angiopoietina-1/análise , Angiopoietina-2/análise , Animais , Apoptose , Contagem de Células , Divisão Celular , Colágeno , Combinação de Medicamentos , Implantes de Medicamento , Células Endoteliais , Expressão Gênica , Regulação da Expressão Gênica , Produtos Finais de Glicação Avançada/sangue , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Laminina , Metaloproteinase 2 da Matriz/genética , Metaloproteinase 9 da Matriz/genética , Camundongos , Camundongos Endogâmicos C57BL , Músculo Liso Vascular/citologia , NF-kappa B/fisiologia , Antígeno Nuclear de Célula em Proliferação/análise , Proteoglicanas , Receptor para Produtos Finais de Glicação Avançada , Receptores Imunológicos/deficiência , Receptores Imunológicos/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Trombospondina 1/análise , Transfecção , Fator A de Crescimento do Endotélio Vascular/administração & dosagem , Fator A de Crescimento do Endotélio Vascular/análise
3.
Am J Alzheimers Dis Other Demen ; 21(3): 197-208, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16869341

RESUMO

Several epidemiological studies have reported moderately increased risks of Alzheimer's disease (AD) in diabetic patients compared with general population. In diabetes mellitus, the formation and accumulation of advanced glycation end products (AGEs) progress more rapidly. Recent understanding of this process has confirmed that interactions between AGEs and their receptor (RAGE) may play a role in the pathogenesis of diabetic complications and AD. The authors have recently found that glyceraldehyde-derived AGEs (AGE-2), which is predominantly the structure of toxic AGEs (TAGE), show significant toxicity on cortical neuronal cells and that the neurotoxic effect of diabetic serum is completely blocked by neutralizing antibody against the AGE-2 epitope. Moreover, in human AD brains, AGE-2 is distributed in the cytosol of neurons in the hippocampus and parahippocampal gyrus. These results suggest that TAGE is involved in the pathogenesis of AD as well as other age-related diseases. In this review, the authors discuss the molecular mechanisms of AD, especially focusing on TAGE-RAGE system.


Assuntos
Doença de Alzheimer/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Produtos Finais de Glicação Avançada/metabolismo , Doença de Alzheimer/fisiopatologia , Animais , Apoptose , Encéfalo/metabolismo , Diabetes Mellitus Tipo 2/fisiopatologia , Humanos , Neurônios/metabolismo , Receptor para Produtos Finais de Glicação Avançada , Receptores Imunológicos
4.
Curr Mol Med ; 6(3): 351-8, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16712480

RESUMO

Diabetic complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis. Chronic hyperglycemia is initially involved in the pathogenesis of diabetic micro- and macro-vascular complications via various metabolic derangements. High glucose increased production of various types of advanced glycation end-products (AGEs). Recently, we found that glyceraldehyde-derived AGEs (AGE-2) play an important role in the pathogenesis of angiopathy in diabetic patients. There is considerable interest in receptor for AGEs (RAGE) found on many cell types, particularly those affected in diabetes. Recent studies suggest that interaction of AGE-2 (predominantly structure of toxic AGEs; TAGE) with RAGE alters intracellular signaling, gene expression, release of pro-inflamatory molecules and production of reactive oxygen species (ROS) that contribute towards the pathology of diabetic complications. We propose three pathways for the in vivo formation of AGE-2 precursor, glyceraldehyde, such as i) glycolytic pathway, ii) polyol pathway, and iii) fructose metabolic pathway. Glyceraldehyde can be transported or can leak passively across the plasma membrane. It can react non-enzymatically with proteins to lead to accelerated formation of TAGE at both intracellularly and extracellularly. In this review, we discuss the molecular mechanisms of diabetic complications, especially focusing on toxic AGEs (TAGE) and their receptor (RAGE) system.


Assuntos
Complicações do Diabetes/metabolismo , Produtos Finais de Glicação Avançada/metabolismo , Diabetes Mellitus/metabolismo , Nefropatias Diabéticas/metabolismo , Neuropatias Diabéticas/metabolismo , Retinopatia Diabética/metabolismo , Produtos Finais de Glicação Avançada/química , Humanos , Modelos Biológicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...